• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by IO Biotech Inc.

    2/6/26 4:10:31 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IOBT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    IO Biotech, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    449778109

    (CUSIP Number)


    02/05/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    449778109


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,027,112.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,027,112.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,027,112.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    449778109


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,027,112.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,027,112.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,027,112.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    449778109


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,027,112.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,027,112.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,027,112.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    IO Biotech, Inc.
    (b)Address of issuer's principal executive offices:

    Ole Maaloes Veh 3, Copenhagen, Denmark 2200
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of IO Biotech, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the shares of Common Stock held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    449778109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 5, 2026. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
    (b)Percent of class:

    5.6%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 5, 2026.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 5, 2026.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 5, 2026.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 5, 2026.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:02/06/2026
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:02/06/2026
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:02/06/2026
    Exhibit Information

    Exhibit 99.1: Joint Filing Agreement

    Get the next $IOBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IOBT

    DatePrice TargetRatingAnalyst
    1/26/2026$0.50Overweight → Neutral
    Piper Sandler
    1/8/2026$0.36Equal-Weight → Underweight
    Morgan Stanley
    9/30/2025$0.39Overweight → Equal-Weight
    Morgan Stanley
    9/30/2025Buy → Hold
    TD Cowen
    11/30/2021$21.00Overweight
    Morgan Stanley
    11/30/2021Outperform
    Cowen & Co.
    11/30/2021$20.00Buy
    Jefferies
    More analyst ratings

    $IOBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Smith David V

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:27:46 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hunter Heidi

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:27:20 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hirth Peter

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/6/25 4:26:55 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    IO Biotech downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded IO Biotech from Overweight to Neutral and set a new price target of $0.50

    1/26/26 10:01:23 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded IO Biotech from Equal-Weight to Underweight and set a new price target of $0.36

    1/8/26 8:40:06 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech downgraded by TD Cowen

    TD Cowen downgraded IO Biotech from Buy to Hold

    9/30/25 8:32:59 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by IO Biotech Inc.

    SCHEDULE 13G - IO Biotech, Inc. (0001865494) (Subject)

    2/6/26 4:10:31 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by IO Biotech Inc.

    8-K - IO Biotech, Inc. (0001865494) (Filer)

    1/30/26 4:53:41 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by IO Biotech Inc.

    SCHEDULE 13D/A - IO Biotech, Inc. (0001865494) (Subject)

    1/23/26 7:05:19 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IO Biotech Provides Corporate Update

    Raymond James engaged as financial advisorReduction in force implemented NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives. The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company's workforce, to reduce operating expenses while the company explores strategic al

    1/30/26 8:05:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces Exploration of Strategic Alternatives

    NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that the company intends to explore a range of strategic alternatives to maximize stockholder value. Strategic alternatives that may be evaluated include, but are not limited to, a merger, a business combination, a sale of assets or other strategic transaction or a liquidation and dissolution. The company is also evaluating a further reduction-in-force and other efforts to significantly reduce the company's operating expenses while the company explores a range of strategic alternative

    1/21/26 5:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

    Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic melanomaFive-year analysis of median progression free survival was 25.5 monthsThese results reinforce the potential of immune-modulatory vaccination NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the publication in Nature Communications of the long-term clinical and immunological outcomes from MM1636, the Phase 1/2 trial evaluating the investigational peptide vaccine IO102-IO103 targeting both

    12/15/25 4:05:00 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hunter Heidi bought $20,884 worth of shares (15,000 units at $1.39) (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    6/2/25 7:53:36 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Ahmad Qasim Iftikhar bought $26,553 worth of shares (31,350 units at $0.85) (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    12/26/24 8:50:34 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Zocca Mai-Britt bought $10,120 worth of shares (12,500 units at $0.81), increasing direct ownership by 33% to 49,891 units (SEC Form 4)

    4 - IO Biotech, Inc. (0001865494) (Issuer)

    12/23/24 6:56:14 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Leadership Updates

    Live Leadership Updates

    View All

    IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

    -- Enrollment Completed Ahead of Schedule --       -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, completed enrollment in its neoadjuvant/adjuvant Phase 2 basket trial (IOB-032/PN-E40). The trial is studying IO102-IO103, the company's lead investigational therapeutic cancer vaccine candidate, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), given before (neoadjuvant) and after (adjuvant) surgery with curative intent in patients with resectab

    1/9/25 8:05:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

    NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company's lead cancer vaccine candidate currently in a pivotal Phase 3 trial. Ms. Shamsaei joins the company's executive team, reporting to IO Biotech CEO Mai-Britt Zocca, Ph.D., and is based in the United States. "Marjan's extensive oncology product commercialization and growth strategy expertise will be invaluable as we progress into the commercia

    4/15/24 8:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

    NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced that Faiçal Miyara, Ph.D., has been appointed as the company's chief business officer. Dr. Miyara, who has more than 17 years of experience in the pharmaceutical industry, will be responsible for global business development activities including strategic partnerships. Dr. Miyara will be based in the United States, report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and be a member of the company's executive team, effective immediately. "We are very excited to welcome

    4/5/24 8:30:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Financials

    Live finance-specific insights

    View All

    IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

    Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients treated with pembrolizumab monotherapy, HR=0.77 (CI 0.58-1.00), (p=0.056), with median PFS (mPFS) of 19.4 months vs. 11.0 months, respectively; the results on the primary endpoint narrowly missed the study's statistical significance threshold of p≤0.045 In patients enrolled in this study without prior neo-adjuvant/adjuvant anti-PD-1 treatment (n=371), patients treated with Cylembio plus pembrolizumab achieved improvement in PFS, HR: 0.74 (CI 0.56-0.98) (nominal p=0.037), with mPFS of 24.8 months vs. 11.0 months for the cont

    8/11/25 8:00:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

    NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, today announced the company will hold a conference call and webcast on Monday, August 11, 2025, at 8:30 AM ET to disclose the topline results of the pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) of its investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine, Cylembio (imsapepimut and etimupepimut, adjuvant) in combination with pembrolizumab vs. pembrolizumab alone as a first-line treatment for unresectable or metastatic (advanced) melanoma. Webcast and Conference Call Information The IO Biotech management team will host a webcast/conference call

    8/10/25 8:00:00 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

    Enrollment in the company's Phase 3 pivotal trial (IOB-013/KN-D18) in advanced melanoma accelerated in the second half of 2022; the company expects to enroll 75% of patients by mid-2023 and fully enroll the trial by the end of 2023.The Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 75% of patients have been randomized; this interim analysis could allow for submission of a Biologics License Application for an accelerated approval in the United States.The company continues to enroll patients in its Phase 2 basket study (IOB-022/KN-D38) evaluating IO102-IO103 in combination with pembrolizumab in patients with non-small cell lung cancer, head and nec

    3/14/23 4:11:47 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IOBT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IO Biotech Inc.

    SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

    11/13/24 5:30:28 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by IO Biotech Inc.

    SC 13D/A - IO Biotech, Inc. (0001865494) (Subject)

    9/17/24 9:01:25 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by IO Biotech Inc. (Amendment)

    SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

    5/14/24 9:35:27 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care